DK1572087T3 - Antistoffer med cancerantigen TMEFF2 og anvendelser deraf - Google Patents

Antistoffer med cancerantigen TMEFF2 og anvendelser deraf

Info

Publication number
DK1572087T3
DK1572087T3 DK03744243T DK03744243T DK1572087T3 DK 1572087 T3 DK1572087 T3 DK 1572087T3 DK 03744243 T DK03744243 T DK 03744243T DK 03744243 T DK03744243 T DK 03744243T DK 1572087 T3 DK1572087 T3 DK 1572087T3
Authority
DK
Denmark
Prior art keywords
antibodies
applications
cancer antigen
tmeff2
antigen tmeff2
Prior art date
Application number
DK03744243T
Other languages
English (en)
Inventor
La Calle Agustin De
Ingrid Caras
Vinay Bhaskar
Debbie Law
Vanitha Ramakrishnan
Richard Murray
Daniel Afar
David Powers
Original Assignee
Pdl Biopharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pdl Biopharma Inc filed Critical Pdl Biopharma Inc
Application granted granted Critical
Publication of DK1572087T3 publication Critical patent/DK1572087T3/da

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3069Reproductive system, e.g. ovaria, uterus, testes, prostate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6817Toxins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A61K47/6869Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from a cell of the reproductive system: ovaria, uterus, testes, prostate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00Preparations for testing in vivo
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77Internalization into the cell

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Reproductive Health (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Toxicology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
DK03744243T 2002-03-08 2003-03-07 Antistoffer med cancerantigen TMEFF2 og anvendelser deraf DK1572087T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US36283702P 2002-03-08 2002-03-08
US43681202P 2002-12-27 2002-12-27
PCT/US2003/007209 WO2003075855A2 (en) 2002-03-08 2003-03-07 Antibodies against cancer antigen tmeff2 and uses thereof

Publications (1)

Publication Number Publication Date
DK1572087T3 true DK1572087T3 (da) 2008-08-25

Family

ID=27807977

Family Applications (1)

Application Number Title Priority Date Filing Date
DK03744243T DK1572087T3 (da) 2002-03-08 2003-03-07 Antistoffer med cancerantigen TMEFF2 og anvendelser deraf

Country Status (15)

Country Link
US (5) US7288248B2 (da)
EP (1) EP1572087B1 (da)
JP (2) JP2006502092A (da)
KR (1) KR101104655B1 (da)
AT (1) ATE395082T1 (da)
AU (1) AU2003252830B2 (da)
CA (1) CA2478683C (da)
DE (1) DE60321041D1 (da)
DK (1) DK1572087T3 (da)
ES (1) ES2305481T3 (da)
IL (1) IL163902A0 (da)
PT (1) PT1572087E (da)
SI (1) SI1572087T1 (da)
WO (1) WO2003075855A2 (da)
ZA (1) ZA200407733B (da)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR19990007806A (ko) * 1995-05-19 1999-01-25 벤슨로버트에이치 전환 성장 인자 α HII
US20040141983A1 (en) * 1999-03-15 2004-07-22 Protein Design Labs, Inc. Compositions against cancer antigen LIV-1 and uses thereof
DE60321041D1 (de) * 2002-03-08 2008-06-26 Pdl Biopharma Inc Antikörper gegen krebsantigen tmeff2 und seine anwendungen
US20030180348A1 (en) * 2002-03-22 2003-09-25 Levinson R. Saul Transcellular drug delivery system
ES2544527T3 (es) 2002-07-31 2015-09-01 Seattle Genetics, Inc. Conjugados de fármacos y su uso para tratar el cáncer, una enfermedad autoinmune o una enfermedad infecciosa
WO2004067564A2 (en) 2003-01-29 2004-08-12 Protein Design Labs, Inc. Compositions against cancer antigen liv-1 and uses thereof
EP3434275A1 (en) 2003-11-06 2019-01-30 Seattle Genetics, Inc. Assay for cancer cells based on the use of auristatin conjugates with antibodies
US20050175619A1 (en) * 2004-02-05 2005-08-11 Robert Duffy Methods of producing antibody conjugates
MXPA06014065A (es) 2004-06-01 2007-01-31 Genentech Inc Conjugados de droga-anticuerpo y metodos.
US8901281B2 (en) 2005-06-17 2014-12-02 Merck Sharp & Dohme Corp. ILT3 binding molecules and uses therefor
WO2007002525A2 (en) * 2005-06-28 2007-01-04 Schering Aktiengesellschaft Tomoregulin antibodies and uses thereof
AU2007345745C1 (en) 2006-06-19 2013-05-23 Merck Sharp & Dohme Corp. ILT3 binding molecules and uses therefor
US20100285335A1 (en) * 2007-02-05 2010-11-11 Humphrey Samkelo Lungisani Sithebe Polycrystalline diamond (pcd) materials
ATE543835T1 (de) 2007-07-16 2012-02-15 Genentech Inc Anti-cd79b-antikörper und immunkonjugate und anwendungsverfahren
ES2528922T3 (es) 2007-07-16 2015-02-13 Genentech, Inc. Anticuerpos anti-CD79b humanizados e inmunoconjugados y métodos de uso
AU2008312457B2 (en) * 2007-10-19 2014-04-17 Genentech, Inc. Cysteine engineered anti-TENB2 antibodies and antibody drug conjugates
PT2247620T (pt) 2008-01-31 2016-08-23 Genentech Inc Anticorpos e imunoconjugados anti-cd79b e métodos de utilização
EP3470534B1 (en) * 2009-01-07 2024-03-20 Arcedi Biotech ApS Enrichment and identification of fetal cells in maternal blood and ligands for such use
US20110159588A1 (en) 2009-12-30 2011-06-30 Kui Lin Methods for Modulating a PDGF-AA Mediated Biological Response
EP3786185A1 (en) 2010-12-06 2021-03-03 Seagen Inc. Humanized antibodies to liv-1 and use of same to treat cancer
US20150030602A1 (en) * 2011-12-23 2015-01-29 Phenoquest Ag Antibodies for the treatment and diagnosis of affective and anxiety disorders
DK3262071T3 (da) 2014-09-23 2020-06-15 Hoffmann La Roche Fremgangsmåde til anvendelse af anti-CD79b-immunkonjugater
AU2017235545A1 (en) 2016-03-15 2018-10-25 Seagen Inc. Combination therapy using a LIV1-ADC and a chemotherapeutic
CR20200564A (es) * 2018-05-24 2021-06-21 Janssen Biotech Inc Anticuerpos anti-tmeff2 monoespecificos y multiespecificos y sus usos
UA128273C2 (uk) 2019-06-07 2024-05-22 Арседі Байотек Апс Спосіб пренатальної діагностики (варанти)
JP2024503924A (ja) * 2021-01-27 2024-01-29 ヤンセン バイオテツク,インコーポレーテツド カリクレイン関連ペプチダーゼ2抗原結合ドメインを含む免疫コンジュゲート及びその使用

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60321041D1 (de) * 2002-03-08 2008-06-26 Pdl Biopharma Inc Antikörper gegen krebsantigen tmeff2 und seine anwendungen

Also Published As

Publication number Publication date
WO2003075855A3 (en) 2006-03-23
US20080044840A1 (en) 2008-02-21
US7288248B2 (en) 2007-10-30
CA2478683C (en) 2016-01-26
US20040096392A1 (en) 2004-05-20
US8257708B2 (en) 2012-09-04
EP1572087A4 (en) 2006-11-02
US20110038864A1 (en) 2011-02-17
EP1572087A2 (en) 2005-09-14
IL163902A0 (en) 2005-12-18
WO2003075855A2 (en) 2003-09-18
AU2003252830B2 (en) 2008-10-09
US7824678B2 (en) 2010-11-02
AU2003252830A1 (en) 2003-09-22
PT1572087E (pt) 2008-07-11
US20080175846A1 (en) 2008-07-24
KR20050002848A (ko) 2005-01-10
US20080160012A1 (en) 2008-07-03
ZA200407733B (en) 2005-10-26
SI1572087T1 (sl) 2008-10-31
US7785816B2 (en) 2010-08-31
JP2006502092A (ja) 2006-01-19
EP1572087B1 (en) 2008-05-14
CA2478683A1 (en) 2003-09-18
ATE395082T1 (de) 2008-05-15
ES2305481T3 (es) 2008-11-01
DE60321041D1 (de) 2008-06-26
JP5192537B2 (ja) 2013-05-08
US7674883B2 (en) 2010-03-09
KR101104655B1 (ko) 2012-01-13
JP2011121950A (ja) 2011-06-23

Similar Documents

Publication Publication Date Title
IL163902A0 (en) Antibodies against cancer antigen tmeff2 and uses thereof
CY1109741T1 (el) Sns-595 και μεθοδοι χρησης αυτου
CY1119291T1 (el) Πολυσθενη αντισωματα και χρησεις για αυτα
CY1120070T1 (el) Μεθοδοi θεραπευτικης αγωγης με τη χρηση συζευγματων αντισωματος εναντι-erbb-μεϋτανσινοειδους
IL200404A (en) Conjugates of antibodies that bind 191p4d12(b)proteins and uses thereof for treating cancer
EP1844077A4 (en) DR5 ANTIBODIES AND THEIR USE
DK1784426T3 (da) Humaniserede anti-beta7-antagonister og anvendelser deraf
CY1112862T1 (el) Θραυσματα μονοσθενους αντισωματος χρησιμα ως θεραπευτικα
TW200510459A (en) RG1 antibodies and uses thereof
DK1383785T3 (da) Rekombinant tumorspecifikt antistof og anvendelse deraf
TNSN08255A1 (en) Anti-mn antibodies and methods of using same
CY1112055T1 (el) Συνθεσεις και μεθοδοι για την διαγνωση και θεραπευτικη αγωγη ογκου πνευμονα
NZ605429A (en) Therapeutic human anti-il-1r1 monoclonal antibody
PT1644484E (pt) Células autólogas de indução de auto-tolerância de origem monocítica e sua utilização em preparações farmacêuticas
CY1110759T1 (el) Παραλλαγες ανοσοσφαιρινων και χρησεις αυτων
BR0011838A (pt) Elementos misturadores estáticos empilhados
EA200701448A1 (ru) Специфически связывающаяся с крипто-антигеном человека молекула (варианты), композиция на ее основе (варианты), способ получения молекулы, способ лечения посредством молекулы (варианты) и способ ингибирования крипто-экспрессии в клетке больного
MX2009009926A (es) Anticuerpo tumor-especifico humano monoclonal.
ATE517340T1 (de) Sätze gegen kurze epitope gerichteter digitaler antikörper sowie diese verwendende verfahren
MXPA04006517A (es) Conjugados que comprenden un anticuerpo especifico para el dominio ed-b de fibronectina y sus usos para la deteccion y tratamiento de tumores.
DE602004027992D1 (de) In metastatischen menschlichen tumorzellen exprimiertes glycoproteinantigen sima135
ATE490785T1 (de) Parathormon-antikörper und damit zusammenhängende verfahren
DE60231971D1 (de) Ndet, und seine verwendung zur behandlung von krebs
ATE505538T1 (de) Dna-vektoren
CY1106200T1 (el) Αντισωματα εναντια σε κασπαση-8, παρασκευη και χρηση τους